IR
46
3
PBI
30
-8
CTAS
36
8
APA
30
5
ROK
46
3
MAT
41
2
AMG
33
-11
FCX
44
4
UHS
50
4
AMGN
42
14
HUM
25
4
ADP
57
2
CMS
57
2
ACN
54
2
ROP
44
6
ROST
60
3
HCA
37
7
SNA
56
3
CHD
34
7
VIX
41
-11
IR
46
3
PBI
30
-8
CTAS
36
8
APA
30
5
ROK
46
3
MAT
41
2
AMG
33
-11
FCX
44
4
UHS
50
4
AMGN
42
14
HUM
25
4
ADP
57
2
CMS
57
2
ACN
54
2
ROP
44
6
ROST
60
3
HCA
37
7
SNA
56
3
CHD
34
7
VIX
41
-11
Financhill
Back

GoodRx Holdings 10K Form

Sell
27

GDRX
GoodRx Holdings

Last Price:
$4.46
Seasonality Move:
-5.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GDRX News And Ratings

See the #1 stock for the next 7 days that we like better than GDRX

GDRX Financial Statistics

Sales & Book Value

Annual Sales: $750.3M
Cash Flow: $71M
Price / Cash Flow: 19.75
Annual Sales: $1.83
Price / Book: 2.44

Profitability

EPS (TTM): -0.03260
Net Income (TTM): $-16.2M
Gross Margin: $683.3M
Return on Equity: -2.23%
Return on Assets: -1.07%

GoodRx Holdings Earnings Forecast

Key GoodRx Holdings Financial Ratios

  • The Gross Profit Margin over the past 6 years for GDRX is 91.08%.
  • The Selling, General & Administrative Expenses for GDRX have been equal to 62.22% of Gross Profit Margin.
  • The Research & Development expenses have been 18.11% of Revenue.
  • The Interest Expense is -639.69% of Operating Income.
  • The Net Earning history of GDRX is -1.18% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

GoodRx Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Technology
Sector: Health Care
Current Symbol: GDRX
Website: goodrx.com

Debt

Debt-to-Equity Ratio: 0.71
Current Ratio: 5.48
Quick Ratio: 5.1

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 11.17

GDRX Technical Analysis vs Fundamental Analysis

Sell
27
GoodRx Holdings (GDRX) is a Sell

Is GoodRx Holdings a Buy or a Sell?

  • GoodRx Holdings stock is rated a Sell
    The current GoodRx Holdings [GDRX] share price is $4.46. The Score for GDRX is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.